Biomarkers may reveal who recovers from Work-Related asthma
NCT ID NCT07006285
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates whether T2 biomarkers, measured in sputum, can predict which people with occupational asthma will go into remission after stopping exposure to workplace triggers. Only about 30% of patients currently recover, and there is no way to predict who will. Researchers will follow adults diagnosed with occupational asthma and compare T2 levels between those who achieve remission and those who do not.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If T2 biomarkers predict remission, doctors could identify which patients will improve after stopping exposure, guiding personalized care.
- What could go wrong
- This is an observational study with no treatment tested, so it cannot prove cause. The results may not apply to all types of occupational asthma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Strasbourg
Strasbourg, 67000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- A robotic back brace could save Caregivers' spines
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?